Title: [Treatment of patients with stage III non-small cell lung cancer: concurrent high-dose chemotherapy and radiotherapy]
Authors: El Sharouni, S Y ×
Aerts, J G J V
Senan, S
De Ruysscher, Dirk
Groen, H J M
Paul, M A
Smit, E F
Vonk, E J A
Verhagen, A F
Schramel, F M N H #
Issue Date: Dec-2008
Publisher: Bohn Stafleu van Loghum BV
Series Title: Nederlands Tijdschrift voor Geneeskunde vol:152 issue:50 pages:2714-2717
Abstract: The treatment of patients with locally advanced non-small cell lung cancer (stage III) has changed significantly in the past few years. Patients with a non-resectable stage IIIA/B tumour are given combined treatment consisting ofchemotherapy and radiotherapy. These can be administered sequentially or concurrently. It has been shown recently that concurrent chemoradiotherapy gives a survival advantage in comparison with sequential chemoradiotherapy. Cisplatin and etoposide are usually the drugs of choice for chemotherapy in patients with stage III cancer. A biologically effective dose of radiotherapy equivalent to 60-66 Gy, over a maximum of 6.5 weeks, should be given. Surgery is possible for a selected group of patients, provided a complete objective mediastinal response has been achieved after chemoradiotherapy and a complete resection appears to be technically feasible. It is recommended to apply this treatment in a research setting. High-dose concurrent chemoradiotherapy is advised as the standard treatment for stage III non-small cell lung cancer in patients in good physical condition.
ISSN: 0028-2162
Publication status: published
KU Leuven publication type: IT
Appears in Collections:Laboratory of Experimental Radiotherapy
× corresponding author
# (joint) last author

Files in This Item:

There are no files associated with this item.

Request a copy


All items in Lirias are protected by copyright, with all rights reserved.